Changchun Targets EV Growth as China’s Auto Industry Consolidation Accelerates 
Honda Leadership Crisis Deepens as Retired Executives Challenge CEO Toshihiro Mibe’s Strategy 
Trump Administration Defends Anthropic AI Restrictions in Ongoing Federal Lawsuit 
OpenAI Files Confidential IPO Draft as AI Giants Race Toward Public Markets 
Japan Producer Prices Surge in May, Strengthening Expectations of BOJ Rate Hike 
Frasers Group Launches €2 Billion Hugo Boss Takeover Offer Amid Control Speculation 
SpaceX IPO Sets Record With $75 Billion Raise, Valuation Hits $1.77 Trillion 
US Stock Futures Rise on Iran Peace Deal Hopes as SpaceX Debuts After Record IPO 
Oil Prices Fall as Trump Signals Iran Deal, Reducing Supply Risk Concerns 
Coupang Hit With Record $409 Million Fine Over Data Breach Affecting 33 Million Users 
Wall Street Slides as U.S.-Iran Tensions Escalate; Tech Stocks Extend Losses in 2026 
SpaceX IPO Demand Surges Past $250 Billion Ahead of Historic Market Debut 
Hanmi Semicon Shares Surge After $33 Million SpaceX Investment 
US Appeals Court Keeps Trump’s 10% Global Tariff in Effect During Ongoing Legal Battle 
Adobe Beats Q2 2026 Estimates, Raises Full-Year Outlook as AI Revenue Surges Despite Stock Drop 
Kremlin Says New EU Sanctions Won’t Hurt Russian Banks 
European Stocks Rise Ahead of ECB Rate Decision as Investors Buy the Dip 
Celltrion’s antibody treatment for COVID-19 has been granted approval for emergency use in Peru. The South Korean pharmaceutical company announced on Monday, Nov. 22, that the Peruvian authorities approved its Regkirona treatment for emergency application on adult patients with COVID-19.
According to Yonhap News Agency, Peru authorized Celltrion’s antibody treatment for emergency use based on recent results of phase three clinical study of the drug. The study was for attaining more comprehensive results for Regkirona’s effectiveness and safety, and since the results were good, it was approved.
The antibody treatment is being administered to patients in the form of an intravenous injection. It was said to be directly injected for 60 minutes.
Peru is the latest country to issue approval on Celltrion’s drug for treating COVID-19. It has already won approval from other states, such as Brazil and Indonesia, for emergency application. In its home base, which is South Korea, Regkirona has already won the authorities’ drug safety conditional approval in February.
One of the best things about the new drug is that it can lower the risk of COVID-19’s progress to severe levels. What’s more, Celltrion previously stated that its antibody treatment could also reduce the recovery time of patients.
Celltrion’s Regkirona is also South Korea’s very first COVID-19 treatment and it secured approval from Peru just a week after receiving marketing approval from the European Commission. The monoclonal antibody treatment was given the go-ahead last week.
Today’s achievement, coupled with Committee for Medicinal Products for Human Use (CHMP) positive opinion for Regdanvimab, underscores our ongoing commitment to addressing the world’s greatest health challenges,” Celltrion Healthcare’s head of medical and marketing, Dr. HoUng Kim, Ph.D., said in a press release. “Typically, the recommendations from the CHMP are passed on to the EC for rapid legally binding decisions within a month or two, however, given the unprecedented times, we have received the EC approval within a day.”
Meanwhile, the medical and marketing chief added that they are currently in talks with contractors and governments in 30 countries more across Asia, Europe, and Latin America. Celltrion said it would continue to work to make sure that COVID-19 patients worldwide will have access to safe and effective treatment.
